Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 6Unknown 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia 2

Interventions

Cytarabine 35Cyclophosphamide 26Etoposide 18Radiotherapy 16Daunorubicin 16Busulfan 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Idarubicin 14Mercaptopurine 12Dexamethasone 12Vincristine 11Thioguanine 9Mitoxantrone 9Doxorubicin 8Asparaginase 8Antilymphocyte Serum 8pegaspargase 7fludarabine phosphate 7Prednisolone 7Polymerase Chain Reaction 7Filgrastim 7Cyclosporine 7Prednisone 6Mycophenolic Acid 5Melphalan 5Leucovorin 5Gene Expression Profiling 5Vindesine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Leukemia × lintuzumab × Clear all
NCT00006084 2013-12-19

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Unknown
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00006045 2013-11-06

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 3 Unknown
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡